4  How concerned are you about patients in your practice being at risk of CV events due to masked hypertension?
4  When you learn about a new drug in the pipeline, do you:
176  Would you use a subsequent entry biologic erythropoietin in place of an originator drug when treating anemia?
589  Which drug should be added to an ACE inhibitor or ARB when managing diabetic hypertension?
193  Would you enroll your patients in a study randomizing them to a phosphorus binder versus placebo to treat hyperphosphatemia in CKD?